Holen Sie sich die Stockscreener-App
41.57
1.75%
-0.74
Handel nachbörslich:
41.57
Schlusskurs vom Vortag:
$42.31
Offen:
$42.08
24-Stunden-Volumen:
1.10M
Relative Volume:
0.80
Marktkapitalisierung:
$3.91B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-11.14
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-7.48%
1M Leistung:
+21.55%
6M Leistung:
+36.65%
1J Leistung:
-29.45%
1-Tages-Spanne:
$41.07
$42.80
1-Wochen-Bereich:
$41.07
$45.96
52-Wochen-Spanne:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
41.57 | 3.98B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Hyperparathyroidism Pipeline 2025: Innovative Clinical Developments by 3+ Global Leaders – DelveInsight | Featuring Shanghai Hengrui Pharmaceutical, Shaanxi Micot Technology, Crinetics Pharmaceuticals - Barchart.com
Crinetics Pharmaceuticals Inc. stock outlook for YEAR2025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
Will Crinetics Pharmaceuticals Inc. benefit from macro trends2025 Risk Factors & Consistent Growth Equity Picks - newser.com
Will Crinetics Pharmaceuticals Inc. stock keep outperforming rivals2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Is it time to cut losses on Crinetics Pharmaceuticals Inc.2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.Analyst Upgrade & Short-Term High Return Strategies - newser.com
Published on: 2025-10-15 10:15:16 - newser.com
Using data tools to time your Crinetics Pharmaceuticals Inc. exitRecession Risk & AI Forecast Swing Trade Picks - newser.com
What recovery options are there for Crinetics Pharmaceuticals Inc.Market Performance Summary & Fast Entry High Yield Stock Tips - newser.com
Why Crinetics Pharmaceuticals (CRNX) Is Up 6.8% After FDA Approval of First Oral Acromegaly Therapy - Sahm
How to use a screener to detect Crinetics Pharmaceuticals Inc. breakouts2025 Technical Overview & Weekly Watchlist for Hot Stocks - newser.com
Published on: 2025-10-13 23:24:35 - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
What candlestick patterns are forming on Crinetics Pharmaceuticals Inc.2025 Dividend Review & Free Community Consensus Stock Picks - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Is it too late to sell Crinetics Pharmaceuticals Inc.Market Trend Summary & Verified Swing Trading Watchlists - newser.com
Crinetics Pharmaceuticals' (CRNX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Will a bounce in Crinetics Pharmaceuticals Inc. offer an exit2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Crinetics stock holds Overweight rating at Piper Sandler after acromegaly drug approval - Investing.com Canada
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com Nigeria
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) - Yahoo Finance
A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly - Yahoo Finance
14 Biotech Stocks with High Potential - Insider Monkey
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month - Sahm
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Using portfolio simulators with Crinetics Pharmaceuticals Inc. includedWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
What MACD and RSI say about Crinetics Pharmaceuticals Inc.Earnings Recap Report & Capital Efficient Trade Techniques - newser.com
Does Crinetics Pharmaceuticals Inc. fit your quant trading model2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Comparing Crinetics Pharmaceuticals Inc. in custom built stock radarsMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized - Sahm
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of Stock - MarketBeat
Crinetics Pharmaceuticals Hits Day High with 16.05% Surge in Stock Price - Markets Mojo
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crinetics Pharmaceuticals Inc-Aktie (CRNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Oct 01 '25 |
Sale |
41.81 |
5,000 |
209,050 |
66,270 |
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):